...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Share transfer RBC
Reply New Message
Prev Message Back To Forum Threaded View Next Message

I would agree that  FMV is more expensive, but also more appropriate with the shares not publicly traded! I have complained vigorously to Zenith that they need to do more to support shareholders!

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply